FDA Approves Groundbreaking RSV Vaccine from GSK for Older Adults
TL;DR Summary
The US FDA has approved the first vaccine for respiratory syncytial virus (RSV), a disease that can be life-threatening for seniors, with an estimated 159,000 adults 65 and older hospitalized each year with RSV in the US. The vaccine, called Arexvy and made by GSK, was found to be 83% effective at preventing lower respiratory tract disease caused by the virus and 94% effective at preventing severe disease in seniors. Three other RSV vaccines for older adults are also in the final phases of testing.
- FDA approves first vaccine for RSV, a moment six decades in the making CNN
- FDA approves GSK's RSV vaccine for older adults, world's first shot against virus CNBC
- FDA approves RSV vaccine for adults ages 60 and up NBC News
- FDA approves the first-ever RSV vaccine STAT
- US FDA approves first RSV vaccine from GSK Reuters
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
7 min
vs 8 min read
Condensed
94%
1,505 → 85 words
Want the full story? Read the original article
Read on CNN